Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganaxolone - Marinus Pharmaceuticals

Drug Profile

Ganaxolone - Marinus Pharmaceuticals

Alternative Names: CCD-1042; Ganaxalone-IV; gnx

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue Pharma
  • Developer Marinus Pharmaceuticals; Purdue Pharma
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antimigraines; Anxiolytics; Neuroprotectants; Pregnanes; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus; Infantile spasms; Fragile X syndrome; Epilepsy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Epilepsy
  • Phase II Fragile X syndrome; Lennox-Gastaut syndrome; Postnatal depression; Status epilepticus
  • Preclinical Angelman syndrome
  • No development reported Post-traumatic stress disorders
  • Discontinued Infantile spasms; Migraine; Neuropathic pain; Partial epilepsies

Most Recent Events

  • 06 Nov 2019 Marinus Pharmaceuticals plans a phase III trial in Status epilepticus, in mid-2020
  • 17 Oct 2019 Pharmacokinetics data from a phase II trial in Status Epilepticus released by Marinus Pharmaceuticals
  • 17 Oct 2019 Marinus Pharmaceuticals plans a phase III trial for Status Epilepticus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top